Cambiar Investors LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,201,835 shares of the biopharmaceutical company’s stock, valued at approximately $39,228,000. Pfizer comprises 2.0% of Cambiar Investors LLC’s holdings, making the stock its 14th largest position.
A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Investors Asset Management of Georgia Inc. GA ADV increased its position in Pfizer by 0.5% during the 4th quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 54,129 shares of the biopharmaceutical company’s stock worth $2,121,000 after purchasing an additional 250 shares during the period. FinTrust Capital Advisors LLC increased its position in Pfizer by 1.1% during the 4th quarter. FinTrust Capital Advisors LLC now owns 24,310 shares of the biopharmaceutical company’s stock worth $952,000 after purchasing an additional 255 shares during the period. McAdam LLC increased its position in Pfizer by 2.7% during the 4th quarter. McAdam LLC now owns 9,727 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 259 shares during the period. Reik & CO. LLC increased its position in Pfizer by 1.4% during the 1st quarter. Reik & CO. LLC now owns 19,160 shares of the biopharmaceutical company’s stock worth $625,000 after purchasing an additional 265 shares during the period. Finally, Prospera Financial Services Inc increased its position in Pfizer by 0.5% during the 4th quarter. Prospera Financial Services Inc now owns 51,834 shares of the biopharmaceutical company’s stock worth $2,031,000 after purchasing an additional 274 shares during the period. 71.66% of the stock is owned by institutional investors.
A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a report on Thursday, March 19th. Barclays upped their price target on Pfizer from $36.00 to $37.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 29th. Standpoint Research upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Morgan Stanley lowered their price target on Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a report on Thursday, April 2nd. Finally, Mizuho restated a “buy” rating and issued a $42.00 price target on shares of Pfizer in a report on Sunday, April 26th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $41.11.
Shares of Pfizer stock traded up $0.09 during trading hours on Monday, reaching $37.73. 4,732,344 shares of the company’s stock were exchanged, compared to its average volume of 22,267,804. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $44.56. The firm has a market capitalization of $208.81 billion, a price-to-earnings ratio of 13.44, a price-to-earnings-growth ratio of 2.93 and a beta of 0.71. The company has a fifty day moving average of $33.85 and a 200-day moving average of $36.76. The company has a current ratio of 0.88, a quick ratio of 0.66 and a debt-to-equity ratio of 0.57.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.09. Pfizer had a return on equity of 26.01% and a net margin of 31.17%. The company had revenue of $12.03 billion for the quarter, compared to analyst estimates of $11.38 billion. During the same quarter in the prior year, the company posted $0.85 EPS. The business’s revenue for the quarter was down 8.3% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.8 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.03%. The ex-dividend date is Thursday, May 7th. Pfizer’s dividend payout ratio is presently 51.53%.
In other news, EVP Douglas M. Lankler sold 65,000 shares of the company’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the completion of the sale, the executive vice president now directly owns 135,375 shares in the company, valued at approximately $5,123,943.75. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Pfizer Inc acquired 312,500 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were purchased at an average price of $16.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.08% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Stock Market – What is a circuit breaker?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.